



October 13, 2021

Aerie Pharmaceuticals Announces Positive Topline Results
for Netarsudil Ophthalmic Solution 0.02% Phase 3 Clinical Trial in Japan

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter “Santen”) announced that Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, hereinafter “Aerie”) announced positive topline results for netarsudil ophthalmic solution 0.02% phase 3 clinical trial in Japan.

Please refer to the link below for detail of the press release.

Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan

<https://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-positive-phase-3-topline-results>

Santen and Aerie have entered into an exclusive development and commercialization agreement for 0.02% netarsudil ophthalmic solution, and 0.02% netarsudil / 0.005% latanoprost combination ophthalmic solution in Japan, along with rights for several other Asian countries.

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.com